A mechanistic multicentre, parallel group, randomised placebo-controlled trial of mesalazine for the treatment of IBS with diarrhoea (IBS-D)

INTRODUCTION: Immune activation has been reported in the mucosa of IBS patients with diarrhoea (IBS-D), and some small studies have suggested that mesalazine may reduce symptoms. We performed a double-blind, randomised placebo-controlled trial of 2 g mesalazine twice daily versus placebo for 3 month...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Gut
Main Authors: Lam, Ching, Tan, Wei, Leighton, Matthew, Hastings, Margaret, Lingaya, Melanie, Falcone, Yirga, Zhou, Xiaoying, Xu, Luting, Whorwell, Peter, Walls, Andrew F, Zaitoun, Abed, Montgomery, Alan, Spiller, Robin
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2016
Teme:
Neurogastroenterology
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4717357/
https://ncbi.nlm.nih.gov/pubmed/25765462
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/gutjnl-2015-309122
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki